FVCBankcorp (NASDAQ:FVCB) reported quarterly earnings of $0.36 per share. This is a 44 percent increase over earnings of $0.25 per share from the same period last year.
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a
